Ascertainment of uninterrupted CAG repeat length and disease-modifying variants in fragment-based genetic testing for Huntington Disease
- PMID: 39669608
- PMCID: PMC11613659
- DOI: 10.1016/j.gimo.2024.101882
Ascertainment of uninterrupted CAG repeat length and disease-modifying variants in fragment-based genetic testing for Huntington Disease
Abstract
Purpose: In Huntington disease (HD), synonymous variants causing loss or duplication of the interrupting CAA codon in the HTT CAG repeat modify disease onset. These variants are undetectable during HD genetic testing, resulting in inaccurate diagnostic reporting of uninterrupted CAG repeat length. Inaccurate reporting of CAG repeat length results in misdiagnosis of individuals with alleles near diagnostic cut-offs. We present a method to identify variant alleles during CAG repeat genotyping, allowing accurate diagnostic reporting of uninterrupted CAG repeat length.
Methods: We used triplet-primed PCR (TP-PCR) to amplify HTT CAG repeat alleles with canonical or noncanonical repeat interruptions and leveraged differences in peak amplification patterns to develop a screening method based on peak height ratio (PHR). We used PHR to screen blood DNA from a cohort of symptomatic individuals with diagnostic CAG repeat lengths of 40 to 41.
Results: TP-PCR enables accurate reporting of uninterrupted CAG repeat length in diagnostic testing by detecting HD alleles with loss or duplication of the CAG repeat interruption.
Conclusion: PHR screening of TP-PCR traces is a cost-effective screening method for detection, ascertainment of uninterrupted HTT CAG repeat length, and accurate diagnostic reporting for individuals with disease-modifying noncanonical CAG repeat interruptions.
Keywords: Genetic modifiers; Huntington disease; Loss of interruption; Triplet-primed PCR; Variant screening.
© 2024 The Authors.
Conflict of interest statement
Michael R. Hayden is the CEO of Prilenia Therapeutics, a private company, and serves on the public boards of Ionis Pharmaceuticals, Oxford Biomedica, AbCellera and 89bio. All other authors declare no conflicts of interest.
Figures
References
-
- Bean L., Bayrak-Toydemir P., ACMG Laboratory Quality Assurance Committee Addendum: American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. Genet Med. 2021;23(12):2461. doi: 10.1038/s41436-020-0893-3. - DOI - PubMed
-
- Caron N.S., Wright G.E.B., Hayden M.R. In: GeneReviews®. Adam M.P., Feldman J., Mirzaa G.M., et al., editors. University of Washington; Seattle: 1998. Huntington disease; pp. 1–34.https://www.ncbi.nlm.nih.gov/books/NBK1305/
LinkOut - more resources
Full Text Sources
